Domain Therapeutics reaches two milestones in multi-target research collaboration with Boehringer Ingelheim
Yposkesi to host roundtable on challenges in gene therapy manufacturing at the Cell and Gene Meeting on the Mesa, October 2-4
Imcyse to present first-in-human phase 1b study results in type 1 diabetes at EASD 2019
Imcyse to present positive results in EAE model of multiple sclerosis at ECTRIMS 2019
Domain Therapeutics invests in Ermium Therapeutics to develop first-in-class CXCR4 candidate for autoimmune diseases
Yposkesi’s viral vectors used in gene therapy-based clinical trial
PDC*line Pharma welcomes Dr Channa Debruyne to its management team as medical director
TreeFrog Therapeutics receives additional €3M non-dilutive funding to mass-produce clinical-grade cell therapies by 2021
